Webinar: Emerging Trends in Radiotherapeutics

Recorded December 19, 2023
Organized by Nusano, this virtual key opinion leader (KOL) event focuses on the future of the radiotherapeutics landscape, a market that is projected to have a $30 billion potential in the next five years.
Suji Jeong PhD (Founding Partner, The SJR Group) moderates the discussion which features Phil Nicklin (Senior Analyst, LifeSci Consulting) and Dr. Ashley Mishoe, PharmD (Vice President of Regulatory Affairs and Quality Assurance, PharmaLogic), and and Dr. Johnnie José Orozco, MD, PhD (Associate Professor, Translational Science and Therapeutics Division, Fred Hutch Cancer Center).
The panelists discuss isotopes representing the next frontier in radiotherapeutics development (astatine-211, lead-212), exploring alternatives to industry staples like lutetium-177 and actinium-225. Their discussions also delve into supply chain complexities, the role of CDMOs in bringing radiotherapeutics to patients, and the optimal timing for commercial-scale product development. A live question and answer session follows the moderated panel discussion.
About Suji Jeong, PhD:
Suji Jeong, PhD is Founding Partner of The SJR Group, a consulting firm specializing in strategy and CFO services for the radiopharmaceuticals industry. Prior to founding The SJR Group, Suji served as a biotechnology equity research analyst at Jefferies, where she was responsible for covering a diverse range of therapeutic sectors, including radiopharmaceuticals. Suji holds a PhD in neuroscience from Northwestern University and began her biotech equity research career at Morgan Stanley.
About Phil Nicklin:
Phil Nicklin is a Senior Analyst at LifeSci Consulting, specializes in evaluating commercial strategies for early-stage biotech and radiopharmaceutical companies with a focus on oncology. He closely tracks all things radiopharmaceuticals, including clinical studies and emerging players in the market. Before joining LifeSci, he worked at Memorial Sloan Kettering Cancer Center, contributing to early-stage clinical trials that encompassed targeted alpha and beta therapies. Phil holds a B.S. in Biological Sciences from Cornell University.
About Dr. Ashley Mishoe, PharmD:
Dr. Ashley Mishoe, PharmD, is a nuclear pharmacist and is currently the Vice President of Regulatory Affairs and Quality Assurance at PharmaLogic, where she oversees all regulatory compliance and quality-related aspects for the company’s manufacturing facilities. She previously served as the Director of the Radiopharmaceutical Facility at the University of California, San Francisco.
About Dr. Johnnie José Orozco:
Dr. Johnnie José Orozco, MD, PhD is a practicing oncologist who studies novel ways to treat blood cancers, and how to make the transplantation of blood-forming stem cells safer and more effective. His research develops radioimmunotherapies that use immune system proteins known as antibodies, stably linked to radionuclides, to selectively target radioactivity to cancer cells, sparing normal tissues. The antibody and its radioactive payload locate and kill tumor cells by damaging their DNA. The goal is to maximize outcomes for cancer patients and minimize off target treatment effects with radioimmunotherapy.